General | VJHemOnc

Omidubicel receives FDA approval for patients with hematological malignancies requiring stem cell transplantation

On April 17, 2023, the U.S. Food and Drug Administration (FDA) approved omidubicel, an allogeneic cord blood-derived cell therapy, for…

ASH press briefing rundown: optimizing pediatric care

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

The Post-EBMT for Trainees VJSessions

Join VJHemOnc for an exclusive session with Nico Gagelmann, Claire Horgan and Yasmina Serroukh, who discuss the newly established EBMT…

Begelomab for steroid-resistant acute GvHD

Hematopoietic stem cell transplantation (HSCT) is an incredibly powerful tool in the treatment of hematological malignancies. Testament to this is…

ASH resources now available for clinicians and researchers during COVID-19 pandemic

In response to the ongoing COVID-19 pandemic, The American Society of Hematology (ASH) have launched a webpage (https://www.hematology.org/covid-19) containing resources…

COVID-19 & HemOnc: an interview with David Marks

The Video Journal of Hematological Oncology (VJHemOnc) interviewed Professor David Marks to discuss the ongoing COVID-19 pandemic currently affecting countries…

features: General